medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

1999, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 1999; 46 (4)

Human immunodeficiency virus type I. Interpretation of «viral load» assays

Barriga AG, Castillo TNP

Language: Spanish
References: 31
Page: 201-208
PDF size: 101.43 Kb.


ABSTRACT

The number of cases of AIDS in Mexico has been estimated around 80,00 in America we have the third place, and worlwide the 13th. The development of sensitive and precise nucleid acid amplification assays the measurement of HIV-1 «viral load» infected patients and powerful new antiretroviral drugs have been esential elements in a favourable change in the monitoring and adjustment of an effective therapy. Viral load assays can be affected by numerous variables of interest and concern to the clinicians treating HIV-1 infected patients, the sources of these variables can be categorized as preanalytical, analytical and post-analytical, like sample collection, processing and storage; the effect of vaccinations and concurrent microbial infections, biological variations; the interpretation of his results; and the election of the most adequate viral load assay in terms of precisions specificity, reproducibility, linearity and cost.


REFERENCES

  1. Magis RC, Bravo GE, Anaya LC, Uribe ZP. La situación del SIDA en México a finales de 1998. SIDA/ETS 1998; 4, 4, 143-155.

  2. Salk J. Prospects for the control of AIDS by immunizing seropositive in individuals. Nature 1987; 327: 473-476.

  3. Mellor JW, Kingsley LA, Rinaldo CRJ. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.

  4. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Eng J Med 1989; 321: 1621-1625.

  5. Welles SL, Jackson JB, Yen-Lieberman P. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996: 174: 696-703

  6. Aboulker JP, Babiker AG, Flande P et al. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999; 13, 565-573.

  7. Aboulker JP, Babiker AG, Brun VF et al. HIV RNA response to antiretroviral treatment in 1,280 participants in the Delta trial: an extendend virologic study. AIDS 1999 13, 57-66.

  8. Ho DD, Neumann AU, Perelson AS. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373, 123-126.

  9. Castillo TNP, Barriga AG, Solís TM, Arumir EC. Carga viral en el síndrome de inmunodeficiencia adquirida. Estudio comparativo de tres métodos. Rev Mex Patol Clin 1998; 45: 3, 155-158.

  10. Van Gemen B, Kievits T, Schukkink R. Quantification of HIV-1 RNA in plasma using NASBA TM during HIV primary infection. J Virol Methods 1993; 43: 177-178.

  11. Vandame AM, Schmit JC, Van Douren S. Quantification of HIV-1 RNA in plasma: Comparable results with the NASBA HIV-1 RNA QT and the Amplicor HIV Monitor test. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 127-139.

  12. Revets H, Marissens D, De Wit S. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR HIV-Monitor and QUANTIPLEX HIV RNA Assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34: 1058-1064.

  13. Schuurman R, Descamps D, Weverling GJ. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34: 3016-3022.

  14. Bush CE, Donovan RM, Markowitz NP. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 23 26.

  15. Mole L, Ripich S, Margolis D. The impact of active, herpes simples virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176: 766-778.

  16. Donova RM, Moore E, Bush CE. Changes in plasma HIV RNA levels and CD4 cell counts after vaccination of pediatric patients. AIDS 1997; 11: 1054-1056.

  17. O’Brie WA, Grovit FK, Namazi A. Human immunodeficiency virus type 1 replication can be increased in peripheral blood of seropositve patients after influenza vaccinatton. Blood 1995; 86: 1082-1089.

  18. Claydon EJ, Bennett J, Gor B. Transient elevation of serum HIV antigen levels associated with intercurrent infection. AIDS 1991; 5: 113-114.

  19. Stapran SI, Hemilton BL, Follanshee SE. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med 1995; 182: 1727-1737.

  20. Mole L, Ripich S, Margolis D. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 17: 766-770.

  21. Raboud JM, Montaner JSG, Conway B. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996; 174: 191-194.

  22. Holodniy M, Mole L, Winters M. Diurnal and short term stability of HIV virus load measure by gene amplification. J Acquir Immune Defic Syndr Hum Retrovirol 1994; 7: 363-368.

  23. Ginocchio CC, Nancy TP, Kaplan MH. Effects of specimen collection, proccesing and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol 1997; 35: 2886-2893.

  24. Holodniy M, Kim S, Katzenstein D. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991; 29; 676-679.

  25. Bruisten SM, Oudshoorn P, Van Swieten P. Stability of HIV-1 RNA in blood during specimen handling and storage prior to amplification by NASBA QT J Virol Methods 1997; 67: 199-207.

  26. Collin ML, Zayati C, Detmer JJ. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995; 226: 120-129.

  27. Yen LB, Brambila D, Jackson B. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS clinical trials group virology laboratories. J Clin Microbiol 1996; 34: 2695-2701.

  28. Armbruster DA, Tillman MD, Hubbs LM. Limit of detection (LOD) limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 1994; 40: 1233-123.

  29. Schwartz DH, Laeyendecker OB, Arango JS. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false positive PCR Lancet 1997; 350: 256-259.

  30. Dunne AL, Crowe SM. Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma AIDS 1997; 11: 126-127.

  31. Coste J, Montes B, Reynes J. Effect of HIV-1 genetic diversity of HIV-1 RNA quantification in plasma comparative evaluation of three commercial assays. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 174-175.




2020     |     www.medigraphic.com